155 related articles for article (PubMed ID: 34956909)
1. A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports.
Wang BR; Wan CL; Liu SB; Qiu QC; Wu TM; Wang J; Li YY; Ge SS; Qiu Y; Shen XD; Xue SL; Li Z
Front Oncol; 2021; 11():797941. PubMed ID: 34956909
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells
Li Z; Zhang J; Zhou M; Li JL; Qiu QC; Fu JH; Xue SL; Qiu HY
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35103292
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism.
Li G; Li D; Yuan F; Cheng C; Chen L; Wei X
Ann Transl Med; 2021 Oct; 9(20):1575. PubMed ID: 34790781
[TBL] [Abstract][Full Text] [Related]
4. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
[TBL] [Abstract][Full Text] [Related]
5. Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment.
Li Z; Wang J; Ge SS; Qiu QC; Du JH; Shan SS; Shen XD; Wan CL; Wang BR; Wu DP; Qiu HY; Xue SL
Front Oncol; 2022; 12():841276. PubMed ID: 35211416
[TBL] [Abstract][Full Text] [Related]
6. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia.
Gu S; Hou Y; Dovat K; Dovat S; Song C; Ge Z
Exp Hematol Oncol; 2023 Feb; 12(1):23. PubMed ID: 36849955
[TBL] [Abstract][Full Text] [Related]
8. The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML Cells.
Urwanisch L; Unger MS; Sieberer H; Dang HH; Neuper T; Regl C; Vetter J; Schaller S; Winkler SM; Kerschbamer E; Weichenberger CX; Krenn PW; Luciano M; Pleyer L; Greil R; Huber CG; Aberger F; Horejs-Hoeck J
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831382
[TBL] [Abstract][Full Text] [Related]
9. Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.
Lun Y; Yang JJ; Wu Y
J Clin Pharm Ther; 2017 Dec; 42(6):786-789. PubMed ID: 28646565
[TBL] [Abstract][Full Text] [Related]
10. HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
Seipel K; Kohler S; Bacher U; Pabst T
Curr Issues Mol Biol; 2023 Aug; 45(9):7011-7026. PubMed ID: 37754227
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia.
Báez-Gutiérrez N; Rodríguez-Ramallo H; Moreno MA; Arboli ER; Abdel-Kader Martín L
Ther Adv Hematol; 2021; 12():20406207211040335. PubMed ID: 34471510
[TBL] [Abstract][Full Text] [Related]
12. Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax.
Zhao J; Wu S; Wang D; Edwards H; Thibodeau J; Kim S; Stemmer P; Wang G; Jin J; Savasan S; Taub JW; Ge Y
Biochem Pharmacol; 2024 Feb; ():116065. PubMed ID: 38373594
[TBL] [Abstract][Full Text] [Related]
13. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
14. FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells.
Asai-Nishishita A; Kawahara M; Tatsumi G; Iwasa M; Fujishiro A; Nishimura R; Minamiguchi H; Kito K; Murata M; Andoh A
Sci Rep; 2023 Sep; 13(1):14454. PubMed ID: 37660196
[TBL] [Abstract][Full Text] [Related]
15. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
16.
Watts J; Lin TL; Mims A; Patel P; Lee C; Shahidzadeh A; Shami P; Cull E; Cogle CR; Wang E; Uckun FM
Front Oncol; 2021; 11():806243. PubMed ID: 35096610
[TBL] [Abstract][Full Text] [Related]
17. Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines.
Mao J; Li S; Zhao H; Zhu Y; Hong M; Zhu H; Qian S; Li J
Am J Transl Res; 2018; 10(8):2567-2578. PubMed ID: 30210693
[TBL] [Abstract][Full Text] [Related]
18. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
19. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
20. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
Li X; Yan X; Guo W; Huang X; Huang J; Yu M; Ma Z; Xu Y; Huang S; Li C; Zhou Y; Jin J
Biomed Pharmacother; 2017 Jun; 90():699-704. PubMed ID: 28419965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
